— Exhibition Review —
The 3-day 22nd China Pharmaceutical Raw Materials Exhibition (CPHI China 2024) came to a successful conclusion on June 21, 2024 at the Shanghai New International Expo Center.
● Exhibition site
Geum Ran Biotech once again participated in this globally acclaimed industry event. The Geum Ran Biotech booth was bustling with visitors from both China and abroad, showing great interest in the chiral compound synthesis technology on display. Geum Ran Biotech utilizes its leading and unique synthetic biology technology to not only improve product quality and purity, but also significantly reduce production costs and environmental impact, contributing to global green and sustainable development. Furthermore, Geum Ran Biotech's rigorous and comprehensive quality control system ensures product quality and safety, earning the trust and praise of its customers.
● Communication and negotiation
During the exhibition, Jinran Biotech also held in-depth discussions and discussions with numerous clients in the pharmaceutical, health care, and cosmetics sectors, establishing extensive partnerships. These clients highly praised Jinran Biotech's technical strength and product quality, and expressed their willingness to further strengthen their collaboration with Jinran Biotech to jointly promote the development of related industries.
● Looking to the future
In short, Jinran Bio's impressive appearance at the exhibition not only showcased its leading and unique technology, but also conveyed its unwavering commitment to green, environmentally friendly, and sustainable development. We have reason to believe that Jinran Bio will continue to make greater contributions to innovation and development in the field of synthetic biological technology in the future.
— Company Introduction—
Founded in June 2020, Jinran Bio is a green, intelligent manufacturing company integrating R&D, production, and sales of high-quality chiral compounds and materials. Leveraging the founding team's over a decade of experience in synthetic biology R&D and industrialization, the company is dedicated to the design, development, production, and sales of novel chiral molecules and materials.
The company currently has four major technology platforms and seven product pipelines, and is committed to helping humans realize their desire to create a better life through biosynthesis!
Post time: Jun-27-2024